European Commission proposes a change to intellectual property rules to let generic drugmakers enter non-EU markets faster. Patent holders are not happy
In a paper setting out its negotiating terms, the government calls for a far reaching-science and innovation pact and says it will respect the remit of the European Court of Justice
The era of prescription digital health has dawned with approval of an app assessed to the same standard of clinical evidence as a conventional drug. Now pharma companies and digital therapy pioneers are forging development and marketing deals, while EU regulators and payers flounder
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.